Bruce E. Sands, MD, MS, FACG

Icahn School of Medicine at Mount Sinai
New York, NY

Disclosure information not submitted.

Presentation(s):

• A0394 - Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results From the UNIFI Long-Term Extension

  Sunday, October 23, 2022
  5:00 PM – 7:00 PM ET

• A0396 - Mirikizumab Improves Mental and Physical Health Outcomes in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies

  Sunday, October 23, 2022
  5:00 PM – 7:00 PM ET

• A0393 - Mirikizumab Improves Quality of Life in Moderately-to-Severely Active UC: Improvement in IBDQ Scores in Participants of LUCENT-1 and LUCENT-2 Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials

  Sunday, October 23, 2022
  5:00 PM – 7:00 PM ET

• A0392 - Ozanimod Is an Efficacious Oral Therapy After 5-ASA Failure in Immunomodulator- and Biologic-Naive Patients With Ulcerative Colitis: Post Hoc Analysis From True North

  Sunday, October 23, 2022
  5:00 PM – 7:00 PM ET

• A0395 - QUASAR Induction Study 1 Cumulative Response to Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis

  Sunday, October 23, 2022
  5:00 PM – 7:00 PM ET

• B0350 - Mirikizumab Improves Work Productivity and Activity Impairment Questionnaire Scores in Moderately-to-Severely Active UC: The LUCENT-1 and LUCENT-2 Randomized, Double-Blind, Placebo-Controlled Phase 3 Studies

  Monday, October 24, 2022
  10:00 AM – 12:00 PM ET

• B0351 - The Effect of Mirikizumab on Fecal Calprotectin and C-Reactive Protein in Phase 3 Studies of Patients With Moderately-to-Severely Active Ulcerative Colitis

  Monday, October 24, 2022
  10:00 AM – 12:00 PM ET

• B0352 - Efficacy of Ozanimod in Vedolizumab-Exposed Patients With Ulcerative Colitis: A Phase 3 True North Post Hoc Analysis

  Monday, October 24, 2022
  10:00 AM – 12:00 PM ET